Form 8-K - Current report:
SEC Accession No. 0000950170-25-083131
Filing Date
2025-06-06
Accepted
2025-06-06 16:30:31
Documents
12
Period of Report
2025-06-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K srpt-20250605.htm   iXBRL 8-K 95821
2 EX-10.1 srpt-ex10_1.htm EX-10.1 9636
3 EX-10.2 srpt-ex10_2.htm EX-10.2 7969
  Complete submission text file 0000950170-25-083131.txt   223150

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20250605.xsd EX-101.SCH 23883
14 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20250605_htm.xml XML 4527
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 251031171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)